Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Part of paid clinical trials in Fullerton, California.
- Sponsor
- HistoSonics, Inc.
- Study ID
- NCT06486454
- Status
- Recruiting
Conditions
- Benign Liver Tumor
- Liver Neoplasms
- Primary Liver Cancer
- Secondary Liver Cancer
- Tumor Liver
Eligibility Criteria
- Sex
- ALL
- Age
- 22 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- HistoSonics Edison System — DEVICEHistotripsy with the HistoSonics Edison System for the full or partial destruction of liver tumors
Study Details
The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure. Sub-studies to the BOOMBOX: Master Study will investigate specific populations and/or clinical questions with more stringent enrollment criteria, standardized testing criteria, and/or follow-up schedule. Any participant enrolled in the BOOMBOX: Master Study that also qualifies for a sub-study may enroll in the sub-study in parallel; sub-studies will be described in separate sub-study protocols. The BOOMBOX: Master Study will collect information about participants before, during, and after the histotripsy treatment procedure. All participants will be followed per standard clinical follow-up based on each site's clinical practice for up to 5 years after the initial histotripsy procedure or until completion of their follow-up in a sub-study, whichever is longer.
Key Dates
- Start date
- Oct 14, 2024
- Status verified
- Jun 2026
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2031
Study Design
- Enrollment
- 5,000 participants (estimated)
Arms
- Arm: HistoSonics Edison System
Primary Outcome Measure
Histotripsy Technical Success [ Time Frame: ≤36 hours post-histotripsy treatment procedure ]
Central Contacts
- Michelle Biedenfeld605-354-1448
- Christine Frederiksen307-262-7118
Locations (30)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Providence St. Jude | Fullerton | California | 92835 | Veronica Aguilar David Park, MD (PRINCIPAL_INVESTIGATOR) |
| Mission Hospital | Mission Viejo | California | 92691 | Kinnedy Houston Kevin Burns, MD (PRINCIPAL_INVESTIGATOR) |
| Hoag | Newport Beach | California | 92663 | Vicki Tan Trushar Patel, MD (PRINCIPAL_INVESTIGATOR) |
| Sutter Bay Hospitals | San Francisco | California | 94107 | Casey Ward, MD (PRINCIPAL_INVESTIGATOR) |
| Providence Saint John's Health Center | Santa Monica | California | 90404 | Joey Dumadag Paul Shin, MD (PRINCIPAL_INVESTIGATOR) |
| AdventHealth Altamonte Springs | Altamonte Springs | Florida | 32701 | - |
| AdventHealth Celebration | Celebration | Florida | 34747 | Andrea Chiriboga Andrew Guzowski, MD (PRINCIPAL_INVESTIGATOR) |
| Lee Health Cancer Institute | Fort Myers | Florida | 33905 | Lee Health Research Department Mark Bloomston, MD (PRINCIPAL_INVESTIGATOR) |
| Baptist Health Miami Cardiac & Vascular Institute | Miami | Florida | 33176 | - |
| Northeast Georgia Medical Center | Gainesville | Georgia | 30501 | Trena Davis Terence Jackson, MD (PRINCIPAL_INVESTIGATOR) |
| RUSH University Medical Center | Chicago | Illinois | 60612 | Karl Villanueva Jordan Tasse, MD (PRINCIPAL_INVESTIGATOR) |
| University of Chicago | Chicago | Illinois | 60637 | Tiana Jackson Abdul Khan, MD (PRINCIPAL_INVESTIGATOR) |
| Willis Knighton Health | Shreveport | Louisiana | 71103 | Briana Barrow Gazi Zibari, MD (PRINCIPAL_INVESTIGATOR) |
| Mass General Brigham | Boston | Massachusetts | 02115 | Maggie Connolly Jiping Wang, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| Henry Ford Health | Detroit | Michigan | 48202 | Atsushi Yoshida, MD (PRINCIPAL_INVESTIGATOR) |
| University of Michigan Health - West | Wyoming | Michigan | 49519 | Jensen Jantz Michael Koets, MD (PRINCIPAL_INVESTIGATOR) |
| Renown Regional Medical Center | Reno | Nevada | 89502 | Katie Buckley Nick Manguso, MD (PRINCIPAL_INVESTIGATOR) |
| Columbia University Irving Medical Center | New York | New York | 10032 | Ihor Hursh Stephen Reis, MD (PRINCIPAL_INVESTIGATOR) |
| NYU Langone Health | New York | New York | 10016 | Stanley Cobos Brock Hewitt, MD (PRINCIPAL_INVESTIGATOR) |
| Weill Cornell Medicine | New York | New York | 10065 | Nishtha Singh Juan Rocca, MD (PRINCIPAL_INVESTIGATOR) |
| University of Rochester Medical Center | Rochester | New York | 14642 | Cristina Jimenez-Soto Koji Tomiyama, MD (PRINCIPAL_INVESTIGATOR) |
| Novant Health | Winston-Salem | North Carolina | 27103 | Alison Rankin David Sindram, MD (PRINCIPAL_INVESTIGATOR) |
| Miami Valley Hospital South | Centerville | Ohio | 45459 | James Ouellette, MD (PRINCIPAL_INVESTIGATOR) |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | Erlind Allkushi Jaekeun Kim, MD (PRINCIPAL_INVESTIGATOR) |
| The Ohio State University | Columbus | Ohio | 43210 | Mina Makary, MD (PRINCIPAL_INVESTIGATOR) |
| Lehigh Valley Hospital | Allentown | Pennsylvania | 18103 | Jessie Panick Errin Hoffman, MD (PRINCIPAL_INVESTIGATOR) |
| St. David's Medical Center | Austin | Texas | 78705 | Krishna Saini Shaun McKenzie, MD (PRINCIPAL_INVESTIGATOR) |
| Henrico Doctors' Hospital | Richmond | Virginia | 23229 | Laurie Cuttino, MD (PRINCIPAL_INVESTIGATOR) |
| Swedish Medical Center | Seattle | Washington | 98122 | Jacob Karr Evan Ong, MD (PRINCIPAL_INVESTIGATOR) |
| University of Wisconsin | Madison | Wisconsin | 53792 | Caitlin Normoyle John Swietlik, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Fullerton, CA
Related Studies
- The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyRecruiting · UMC Utrecht · Pittsburgh, Pennsylvania
- ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular CarcinomaPHASE1/PHASE2 · Recruiting · Eureka Therapeutics Inc. · San Francisco, California
- Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver TumorsPHASE2 · Recruiting · john eisenbrey · Philadelphia, Pennsylvania
- An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver CancerRecruiting · City of Hope Medical Center · Duarte, California